Business
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking\nSOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV core inhibitor program will be featured in one oral and two poster presentations, including one late breaking, during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®. The presentations include updates from the clinical studies of vebicorvir (VBR) and ABI-H3733, as well as the newly selected preclinical core inhibitor candidate, ABI-4334. AASLD will be hosted virtually November 12-15, 2021. “The Liver Meeting offers a valuable opportunity to further advance our understanding of HBV and liver disease, while gaining access to the latest cutting-edge research from the world’s leading liver disease experts,” said John McHutchison, AO, MD, chief executive officer and president of Assembly Bio. “We continue to believe that therapeutics targeting the HBV core protein will offer a long-awaited breakthrough for individuals living with HBV, and we are excited to share what we’ve learned through our latest findings. This year, we’re also looking forward to more formally introducing the AASLD community to ABI-4334, a new compound with a potential best-in-class preclinical profile including single digit nanomolar potency against the formation of cccDNA.” Oral Presentation #96: HBV pgRNA and DNA both rebound immediately following discontinuation of the core inhibitor vebicorvir despite continued NrtI treatment in patients with HBeAg positive chronic hepatitis B virus infection: Findings from a Phase 2 open label studyPresenter: Man-Fung Yuen, MD, PhD, DSc, Queen Mary Hospital, University of Hong KongSession: Parallel 13: Novel HBV Therapies and Approaches Date and Time: Sunday, November 14, 2021, 10:00 AM – 11:30 AM ET Poster Presentation #842: Safety and pharmacokinetics of ABI-H3733, a novel 2nd-generation HBV core inhibitor: Results from a Phase 1a study in healthy volunteersPresenter: Edward Gane, MBChB, MD FRACP, MNZM, New Zealand Liver Transplant Unit, Auckland City Hospital, New ZealandSession: Hepatitis B: Therape...